Electric-aircraft maker Beta Technologies said Friday, July 10, that it completed the first operational flights in the federal government’s electric air-taxi pilot program, using its all-electric plane to carry manufactured transplant organs between airports in Maryland and Virginia. The announcement came in a company release quoting founder and chief executive Kyle Clark, who framed the trips as proof that everyday medical deliveries can move by electric flight at far lower cost.

The flights, which totaled about 275 nautical miles, moved organs produced by United Therapeutics, a longtime Beta customer that has for years looked for faster ways to transport organs intended for human transplant. “Today’s successful missions set the stage for routine medical applications through electric flight at a much lower cost nationwide,” Clark said. The trips were flown with Beta’s ALIA aircraft, the conventional-takeoff model that lands like a regular plane rather than lifting off vertically.

The mission marks the real-world start of a program the industry has been waiting on since the spring. President Donald Trump created the effort through an executive order last year, and the Department of Transportation and Federal Aviation Administration announced the first project selections in March. The three-year initiative spans eight projects across 26 states and lets companies fly aircraft that have not yet earned full FAA certification, gathering the operational data regulators need to write permanent rules. Officials had said flights would begin this summer; Beta’s Friday missions are the first to actually get off the ground.

Beta is the most active participant by a wide margin, selected for seven of the eight projects — more than any competitor. That reach is central to the business case Clark has pitched to investors. When the selections were announced, he said the program would let Beta begin aircraft operations a full year earlier than planned, and the stock jumped nearly 12% that day. The company’s projects range from medical equipment runs across Vermont’s Lake Champlain to cargo and offshore energy flights along the Gulf Coast to a dozen operational concepts with the Port Authority of New York and New Jersey, including one based at a Manhattan heliport.

For the broader industry, the practical appeal is the chance to fly commercially useful missions before certification, which has proven slow and expensive to obtain. Beta’s own eVTOL aircraft — the vertical-takeoff model most people picture when they hear “flying taxi” — is not expected to be certified until 2028. Its conventional-takeoff plane is on track for 2027. The pilot program effectively lets the company build a track record and a customer base in the gap, moving cargo, medical supplies and eventually passengers while the paperwork catches up.

The financial backdrop is far less cheerful than the flight footage. Beta shares have lost roughly half their value since the company’s initial public offering in November, which raised about $1.1 billion. The pain is industry-wide: rivals Joby Aviation and Archer Aviation are each down more than a third this year, and the United Kingdom’s Vertical Aerospace has shed 68% of its value. Appetite for the sector has cooled as investors wait for revenue to catch up with the promises, and some companies are tangled in court battles that have pushed timelines further out.

Revenue remains thin for now. Beta earned $35.6 million last year, with government contracts and United Therapeutics historically accounting for nearly all of it. The company has been working to broaden that base — selling its electric motors to other aircraft makers, including a roughly $1 billion motor deal with Eve Air Mobility, and installing charging stations at airports around the country. Customers such as UPS and Air New Zealand have placed firm orders for nearly 300 aircraft worth more than $1 billion, with options for hundreds more, but those deliveries depend on the same certification milestones still years away.

The organ-transport flights point to where the near-term money most likely sits: not glamorous downtown air taxis, but quiet, high-value cargo runs where speed and cost genuinely matter. Hospitals and organ networks operate on tight clocks, and a cheaper, cleaner way to move a transplant across a metro area is a concrete business, not a concept video. Whether that early revenue arrives fast enough to steady Beta’s share price — and the sector’s — is the open question. Friday’s flights answered a different one: after years of promises, the aircraft are finally carrying real cargo for real customers under a federal program built to get them there.

JBizNews Desk | Burlington, Vt. © JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.